.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Cantor Fitzgerald
QuintilesIMS
Cipla
US Army
Cerilliant
Citi
Moodys
Accenture
US Department of Justice

Generated: December 15, 2017

DrugPatentWatch Database Preview

CAPRELSA Drug Profile

« Back to Dashboard

When do Caprelsa patents expire, and when can generic versions of Caprelsa launch?

Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-eight patent family members in thirty-eight countries and nine supplementary protection certificates in seven countries.

The generic ingredient in CAPRELSA is vandetanib. Two suppliers are listed for this compound. Additional details are available on the vandetanib profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► SubscribeYY► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CAPRELSA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,897,210 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,673,803 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CAPRELSA

Country Document Number Estimated Expiration
European Patent Office1753431► Subscribe
Czech Republic9901039► Subscribe
Spain2330025► Subscribe
South Korea20070034499► Subscribe
Germany602005016105► Subscribe
Poland332385► Subscribe
Switzerland0929530► Subscribe
Malaysia138868► Subscribe
Australia4561397► Subscribe
Hungary9902850► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CAPRELSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/036United Kingdom► SubscribePRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217
00543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
2012015,C1244647Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
12/029Ireland► SubscribePRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
2012000057Germany► SubscribePRODUCT NAME: VANDETANIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
C0048France► SubscribePRODUCT NAME: VANDETANIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/11/749/002 20120217
0543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
2012015Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
90028-8Sweden► SubscribePRODUCT NAME: VANDETANIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/11/749/001 20120217
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Mallinckrodt
Johnson and Johnson
Chinese Patent Office
Accenture
AstraZeneca
Farmers Insurance
Cantor Fitzgerald
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot